
 
 
 
 
 
 
 
 
   
 1. A compound of the formula   or a pharmaceutically acceptable salt thereof.  
 
     
 2. A pharmaceutical composition comprising a compound of the formula   or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.  
 
     
 3. A compound of Formula I:    wherein, W1, W2 and W3 is each independently selected from   The chain from the tricycle may terminate at W3, W2 or W1 with W3, W2 or W1 respectively being either -CH=O or -CH2OH;  A is selected from -NH--, -NCH2R1, -NC(O)R1;      R1 is selected from C1-6 alkyl, C2-6 alkene, aryl or heteroaryl;      R2, R3, and R4 is each independently selected from H, R5, -C(O)R6 R5 is each independently selected from C1-6 alkyl, C2-7 alkalene, aryl or heteroaryl;   R6 is each independently selected from H, C1-6 alkyl, C2-7 alkalene, aryl or heteroaryl; or a pharmaceutically acceptable salt thereof.  
 
     
 4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein A is NH.  
 
     
 5. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein A is -NCH2R1.  
 
     
 6. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein A is -NC(O)R1.  
 
     
 7. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R2 is H.  
 
     
 8. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R3 is H.  
 
     
 9. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R4 is H.  
 
     
 10. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R2, R3 and R4 are each H.  
 
     
 11. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R2, R3 and R4 are each H, and W1 is -CH =CH-.  
 
     
 12. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R2, R3 and R4 are each H, and W2 is -CH =CH-.  
 
     
 13. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R2, R3 and R4 are each H, and W3 is -CH =CH-.  
 
     
 14. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein A is NH and R2, R3 and R4 are each H.  
 
     
 15. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein A is NH, each of W', W2, and W3 is -CH =CH-.  
 
     
 16. A compound selected from the group consisting of:                 
 
     
 17. A pharmaceutical composition comprising the compound of any one of claims 3 to 16 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.  
 
     
 18. A farnesyl dibenzodiazepinone obtained by a method comprising a) cultivating Micromonospora sp. strain [S01]046, wherein said cultivation is performed under aerobic conditions in a nutrient medium comprising at least one source of carbon atoms and at least one source of nitrogen atoms;  and b) isolating a farnesyl dibenzodiazepinone from the bacteria cultivated in step (a).  
 
     
 19. The farnesyl dibenzodiazepinone of claim 18 that generates NMR spectra essentially as shown in Figure 3.  
 
     
 20. A process for making the compound of claim 1, comprising cultivation of Micromonospora sp. strain 046-EC011, in a nutrient medium comprising at least one source of carbon atoms and at least one source of nitrogen atoms, and isolation and purification of said compound.  
 
     
 21. A process for making a compound of claim 1, comprising cultivation of Micromonospora sp. strain [S01]046 in a nutrient medium comprising at least one source of carbon atoms and at least one source of nitrogen atoms, and isolation and purification of said compound.  
 
     
 22. The process of claim 21, wherein said cultivation occurs under aerobic conditions.  
 
     
 23. The process of claim 21, wherein said carbon atom and said nitrogen atom sources are chosen from the components shown in Table 16.  
 
     
 24. The process of claim 21, wherein said cultivation is carried out at a temperature ranging from 18°C to 40°C.  
 
     
 25. The process of claim 21, wherein said cultivation is carried out at a pH ranging from 6 to 9.  
 
     
 26. Micromonospora sp. having IDAC Accession No. 231203-01 or IDAC      Accession No. 070303-01.  
 
     
 27. A method of inhibiting the growth of a cancer cell, comprising contacting said cancer cell with a compound of claim 3, such that growth of said cancer cell is inhibited.  
 
     
 28. A method of inhibiting the growth of a cancer cell, comprising contacting said cancer cell with a compound of claim 1, such that growth of said cancer cell is inhibited.  
 
     
 29. A method of inhibiting the growth of a cancer cell in a mammal, comprising administering the compound of claim 3 to a mammal comprising a cancer cell, such that growth of said cancer cell is inhibited in said mammal.  
 
     
 30. A method of inhibiting the growth of a cancer cell in a mammal, comprising administering the compound of claim 1 to a mammal comprising a cancer cell, such that growth of said cancer cell is inhibited in said mammal.  
 
     
 31. A method of treating a pre-cancerous or cancerous condition in a mammal, comprising the step of administering to said mammal a therapeutically effective amount of the compound of claim 3, such that a pre-cancerous or cancerous condition is treated.  
 
     
 32. A method of treating a pre-cancerous or cancerous condition in a mammal, comprising the step of administering to said mammal a therapeutically effective amount of the compound of claim 1, such that a pre-cancerous or cancerous condition is treated.  
 
     
 33. A method of treating a bacterial infection in a mammal, comprising administering a therapeutically effective amount of the compound of claim 3 to said mammal having a bacterial infection, such that said bacterial infection is treated.  
 
     
 34. A method of treating a bacterial infection in a mammal, comprising administering a therapeutically effective amount of the compound of claim 1 to said mammal having a bacterial infection, such that said bacterial infection is treated.  
 
     
 35. A method of reducing inflammation in a mammal, comprising administering to a mammal having inflammation a therapeutically effective amount of the compound of claim 3, such that said inflammation is reduced.  
 
     
 36. A method of reducing inflammation in a mammal, comprising administering to a mammal having inflammation a therapeutically effective amount of the compound of claim 1, such that said inflammation is reduced.  
 
     
 37. An isolated polynucleotide comprising SEQ ID NOs. 1, 64 and 73, wherein said polynucleotide encodes a polypeptide that participates in a biosynthetic pathway for a farnesyl dibenzodiazepinone.  
 
     
 38. An isolated, purified or enriched nucleic acid for production of a farnesyl dibenzodiazepine, said nucleic acid selected from the group consisting of:     a) SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 66, 68, 70, 72, 75, 77, 79, 81, 83, 85, 87 and 89; b) a nucleic acid encoding a polypeptide of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86 and 88; c) a nucleic acid that is at least 75% identical to a nucleic acid of a) or b), and which encodes a polypeptide having the same biological function as a polypeptide of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86 or 88 respectively; d) a nucleic acid that is complementary to a nucleic acid of a), b) or c).  
 
     
 39. A nucleic acid sequence encoding a polypeptide selected from the group consisting of:   a) SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86 and 88; b) polypeptides that are at least 85% identical to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86 or 88, and having the same biological function as a polypeptide of SEQ ID    NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86 and 88.  
 
     
 40. A nucleic acid sequence of claim 38 or 29 encoding a polypeptide selected from the group consisting of:   a) SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80 and 82; and b) polypeptides that are at least 85% identical to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80 and 82 and having the same biological function as a polypeptide of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80 or 82.  
 
     
 41. A nucleic acid sequence of claim 38, 39 or 40 comprising a sequence selected from the group consisting of:   a) SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 66, 68, 70, 72, 75, 77, 79, 81, 83, 85, 87 and 89; and b) a sequence that is at least 85% identical to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 66, 68, 70, 72, 75, 77, 79, 81, 83, 85, 87 or 89, and encodes a polypeptide having the same biological function as a polypeptide of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86 and 88.  
 
     
 42. A nucleic acid sequence of any one of claims 38 to 41 comprising a sequence selected from the group consisting of:   a) SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 66, 68, 70, 72, 75, 77, 79, 81, 83, 85, 87 and 89; and b) a sequence that is at least 90% identical to SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 66, 68, 70, 72, 75, 77, 79, 81, 83, 85, 87 and 89.  
 
     
 43. A nucleic acid sequence of any one of claims 38 to 42 comprising a sequence selected from the group consisting of:   a) SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 66, 68, 70, 72, 75, 77, 79, 81, 83, 85, 87 and 89; and b) a sequence that is at least 98% identical to a SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 66, 68, 70, 72, 75, 77, 79, 81, 83, 85, 87 or 89.  
 
     
 44. A nucleic acid sequence encoding at least two of the nucleic acid sequences of any one or claims 38 to 43.  
 
     
 45. A nucleic acid sequence encoding at least three of the nucleic acid sequences of any one of claims 38 to 43.  
 
     
 46. A nucleic acid sequence encoding at least five of the nucleic acids of any one of claims 38 to 43.  
 
     
 47. Use of a nucleic acid of any one of claims 38 to 46 for the production of a farnesyl dibenzodiazepine.  
 
     
 48. An expression vector comprising a nucleic acid of any one or claims 38 to 46.  
 
     
 49. An isolated host cell transformed with an expression vector of claim 48.  
 
     
 50. A bacterial host cell transformed with an expression vector of claim 48.  
 
     
 51. The host cell of claim 49 or 50 wherein said host cell is selected from species of the genera Pseudomonas and Streptomyces.  
 
     
 52. The host cell of claim 49 or 50 wherein the host cell is E. coli.  
 
     
 53. An isolated polypeptide sequence selected from the group consisting of: a) SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86 and 88; and b) a polypeptide having at least 75% identity to a polypeptide of SEQ ID   NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84 or 86, and having the same biological function as the polypeptide of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84 or 86 respectively.  
 
     
 54. An isolated polypeptide sequence selected from the group consisting of: a) SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86, 88; and b) polypeptide having at least 85% identity to a polypeptide of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86 or 88, and having the same biological function as the polypeptide as SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 24, 26, 38, 40, 42, 44, 46, 48 or 50 respectively.  
 
     
 55. An isolated polypeptide sequence selected from the group consisting of: a) SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86, 88; and b) a polypeptide having at least 85% identity to a polypeptide of SEQ ID   NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86 or 88, and having the same biological function as the polypeptide of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86 or 88 respectively.  
 
     
 56. An isolated polypeptide sequence selected from the group consisting of:   a) SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86 and 88; and b) a polypeptide having at least 90% identity to a polypeptide of SEQ ID   NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86 or 88.  
 
     
 57. An isolated polypeptide sequence selected from the group consisting of: a) SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86 and 88; b) a polypeptide having at least 95% identity to a polypeptide of SEQ ID   NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 41, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 70, 71, 74, 76, 78, 80, 82, 84, 86 or 88.  
 
     
 58. A method of making a polypeptide having a sequence selected from the polypeptides of any one of claims 53 to 57 comprising introducing into a host cell in vitro a nucleic acid encoding said polypeptide, said nucleic acid being operably linked to a promoter.  
 
     
 59. A method of making a polypeptide having a sequence selected from the polypeptides of any one of claims 53 to 57 comprising introducing into an isolated host cell a nucleic acid encoding said polypeptide, said nucleic acid being operably linked to a promoter.  
 
     
 60. A method of making a polypeptide having a sequence selected from the polypeptides of any one of claims 53 to 57 comprising introducing into a bacterial host cell a nucleic acid encoding said polypeptide, said nucleic acid being operably Pinked to a promoter.  
 
     
 61. Use of at least one polypeptide of any one of claim 53 to 57 for the production of a farnesyl dibenzodiazepine.  
 
     
 62. Use of at least two polypeptides of any one of claims 53 to 57 for the production of a farnesyl dibenzodiazepine.  
 
     
 63. Use of at least three polypeptides of any one of claims 53 to 57 for the production of a farnesyl dibenzodiazepine.  
 
     
 64. Use of at least five polypeptides of any one of claims 53 to 57 for the production of a farnesyl dibenzodiazepine.  
 
     
 65. Use according to any one of claims 53 to 57 wherein the farnesyl dibenzodiazepine is the compound ECO-04601.  
 
     
 66. Cosmid 046KM deposited under IDAC accession no. 250203-06.  
 
     
 67. Cosmid 046KQ deposited under IDAC accession no. 250203-07.  
 
     
 68. The cosmid of claim 66 or 67, wherein said cosmid is inserted into a prokaryotic host for expressing a product.  
 
     
 69. The cosmid of claim 68, wherein said host is E. coli, Streptomyces lividans, Streptomyces griseofuscus, Streptomyces ambofuchsus, Actinomycetes, Bacillus, Corynebacteria or Thermoactinomyces.  
 
     
 70. A DNA which hybridizes under stringent hybridization conditions to the DNA  of the cosmid of claim 66 or 67; and that encodes a biosynthetic pathway for the production of a farnesyl dibenzodiazepine.  
 
     
 71. A method for increasing the yields of a farnesyl dibenzodiazepine using the cosmids of claim 66 or 67, said method comprising the steps of transforming a prokaryotic host with the cosmid of claim 66 or 67; and culturing the transformed prokaryotic host under conditions which result in the expression of farnesyl dibenzodiazepine.  
 
     
 72. The polypeptide of any one of claims 53 or 57, wherein said polypeptide participates in a biosynthetic pathway for a farnesyl dibenzodiazepinone.  
 
     
 73. An expression vector comprising one or more of the polynucleotides of claims 38 to 46.  
 
     
 74. A recombinant prokaryotic organism comprising one or more expression vectors of claim 73.  
 
     
 75. The organism of claim 74, wherein said organism is an actinomycete.  
 
     
 76. The organism of claim 74 or 75, wherein said organism requires said expression vector to synthesize a farnesyl dibenzodiazepinone.  
 
     
 77. A method of synthesizing a farnesyl dibenzodiazepinone de novo in a prokaryote, comprising the steps of: (a) providing a prokaryote that is incapable of synthesizing a farnesyl dibenzodiazepinone; (b) transforming said prokaryote with an expression vector of claim 75; and (c) culturing said prokaryote; wherein said culturing results in the synthesis of said farnesyl dibenzodiazepinone in said prokaryote.  
 
     
 78. The method of claim 77, wherein said prokaryote is an actinomycete.  
 
     
 79. The method of claim 77, wherein said vector expresses a polypeptide of any one of claims 53 to 57.  
 
   
 
 
 
 
 
 
 
 
